Production of Alpha Emitters for Targeted Alpha Therapy

被引：29
|
作者：
Morgenstern, A. [1 ]
Abbas, K. [2 ]
Bruchertseifer, F. [1 ]
Apostolidis, C. [1 ]
机构：
[1] European Commiss, Joint Res Ctr, Inst Transuranium Elements, POB 2340, D-76125 Karlsruhe, Germany
[2] European Commiss, Joint Res Ctr, Inst Hlth & Consumer Protect, I-21020 Ispra, VA, Italy
来源：
CURRENT RADIOPHARMACEUTICALS | 2008年 / 1卷 / 03期
关键词：
Targeted alpha therapy; alpha emitter; production; uranium-230; thorium-227; thorium-226; actinium-225; radium-223; bismuth-213; lead-212; bismuth-212; astatine-211; terbium-149;
D O I：
10.2174/1874471010801030135
中图分类号：
R9 [药学];
学科分类号：
1007 ;
摘要：
Targeted alpha therapy (TAT) is a promising approach for the treatment of cancer and infectious diseases. The availability of suitable alpha emitting isotopes in clinically relevant amounts is a main prerequisite for further development of TAT and its widespread clinical application. Several alpha emitting isotopes have been proven effective in preclinical studies and/or clinical trials, including (225) Ac / Bi-213, U-230 / Th-226, Th-227 / Ra-223, Pb-212 / Bi-212, At-211 and Tb-149. Here we give an overview on methods for the production of these nuclides, describe advantages and limitations of the various processes and give an outlook on future availability and isotope supply.
引用
收藏
页码：135 / 143
页数：9
相关论文
共 50 条
  • [41] Intralesional targeted alpha therapy for metastatic melanoma
    Allen, BJ
    Raja, C
    Rizvi, S
    Li, Y
    Tsui, W
    Graham, P
    Thompson, JF
    Reisfeld, RA
    Kearsley, J
    Morgenstern, A
    Apostolidis, C
    CANCER BIOLOGY & THERAPY, 2005, 4 (12) : 1318 - 1324
  • [42] EClinical Trials of Targeted Alpha Therapy for Cancer
    Allen, Barry J.
    REVIEWS ON RECENT CLINICAL TRIALS, 2008, 3 (03) : 185 - 191
  • [43] Actinium-225 in Targeted Alpha Therapy
    Rahman, A. K. M. Rezaur
    Babu, Mahathe Hasan
    Ovi, Mustofa Khalid
    Zilani, Md. Mahiuddin
    Eithu, Israt Sultana
    Chakraborty, Amit
    JOURNAL OF MEDICAL PHYSICS, 2024, 49 (02) : 137 - 147
  • [44] An Appendix of Radionuclides Used in Targeted Alpha Therapy
    Ferrier , Maryline G.
    Radchenko, Valery
    JOURNAL OF MEDICAL IMAGING AND RADIATION SCIENCES, 2019, 50 (04) : S58 - S65
  • [45] The next generation of radioimmunotherapy: Targeted alpha therapy
    Molnar, I.
    Burak, E.
    Forbes, J.
    Simms, R.
    Valliant, J.
    ANNALS OF ONCOLOGY, 2018, 29 : 6 - 6
  • [46] Targeted Alpha Therapy with Thorium-227
    Frantellizzi, Viviana
    Cosma, Laura
    Brunotti, Gabriele
    Pani, Arianna
    Spanu, Angela
    Nuvoli, Susanna
    De Cristofaro, Flaminia
    Civitelli, Liana
    De Vincentis, Giuseppe
    CANCER BIOTHERAPY AND RADIOPHARMACEUTICALS, 2020, 35 (06) : 437 - 445
  • [47] Preclinical targeted alpha therapy for subcutaneous melanoma
    Allen, BJ
    Rizvi, SMA
    Tian, Z
    MELANOMA RESEARCH, 2001, 11 (02) : 175 - 182
  • [48] Development of GGAG alpha camera system for targeted alpha radionuclide therapy research
    Yamamoto, S.
    Watabe, T.
    Kaneda-Nakashima, K.
    Shirakami, Y.
    Ooe, K.
    Toyoshima, A.
    Teramoto, T.
    Shinohara, A.
    Hatazawa, J.
    JOURNAL OF INSTRUMENTATION, 2021, 16 (06):
  • [49] Targeted Radioimmunotherapy and Theranostics with Alpha Emitters (vol 50, pg 41, 2019)
    Pandit-Taskar, N.
    JOURNAL OF MEDICAL IMAGING AND RADIATION SCIENCES, 2021, 52 (01) : 152 - 152
  • [50] Production, purification and formulation of nanoradiopharmaceutical with 211At: An emerging candidate for targeted alpha therapy
    Ghosh, Sanchita
    Banerjee, Debashis
    Guleria, Apurav
    Chakravarty, Rubel
    NUCLEAR MEDICINE AND BIOLOGY, 2024, 138
12345